Sorry, you need to enable JavaScript to visit this website.
Sort by
Sort by

Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”): Disclosure of change in the Senior Management of the Company

The Company has informed BSE and NSE pursuant to appointment of Ms. Mansi Khanna as Chief Operating Officer of Dr. Reddy's and Nestlé Health Science Limited (“JV Company”), in line with the definitive agreement dated 25th April 2024 (“JV Agreement”) to form a joint venture between Nestlé India Limited (“Nestlé India”) and Dr. Reddy’s Laboratories Limited (“DRL”) and Business Transfer Agreement (“BTA”) entered between Nestlé India and the JV Company, this is to inform you that Ms. Mansi Khanna ceased to be Head of Nestlé Health Science Business of the Company (Senior Management Personnel) effective from 1st August 2024.

The details of the JV Agreement and BTA has been separately communicated to the stock exchanges vide our letter no. PKR:SG 52:24 dated 25th April 2024 and PKR:SG: 75:24 dated 1st August 2024. Details in accordance with the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 is given in Annexure - I to this letter.

This is in compliance with Regulation 30 read with Para A of Part A of Schedule III of the Listing Regulations.

PDF file of the letter submitted to Stock Exchange